Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, has been approved by the FDA and is expected to be launched in the United States in the second quarter of 2019. In clinical trials of Rocklatan™ the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan™ including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. Aerie is headquartered in Durham, NC.
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.
Carl Zeiss Meditec
Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has collaboration agreements with Regeneron Pharmaceuticalsand Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.
Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases.
To learn more, visit https://www.gene.com/
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Headquartered in Leuven, Belgium, Oxurion is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company.
Piper Jaffray (NYSE: PJC) is a leading investment bank focused on mergers and acquisitions, public offerings, public finance, institutional brokerage, investment management and research. Founded in 1895, the firm is headquartered in Minneapolis with offices across the U.S. and in London, Aberdeen, Zurich and Hong Kong.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. Pre-clinical data suggest that risuteganib (Luminate®), Allegro’s lead investigational anti-integrin compound in retina, simultaneously acts on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as diabetic macular edema (DME) and intermediate dry age-related macular degeneration (intermediate dry AMD). Risuteganib successfully completed two Phase 2 DME studies and is currently being evaluated in a US Phase 2 intermediate dry AMD study. Allegro is preparing to expand its anti-integrin portfolio into new ocular therapeutic areas.
Eyevensys is a clinical stage biotechnology company developing its innovative EyeCET platform to enable sustained intraocular production of therapeutic proteins to treat ophthalmic diseases.
Eyevensys’ EyeCET gene therapy technology uses electrotransfection to deliver protein coding plasmids, non-viral, into the ciliary muscle of the eye. This approach facilitates the sustained production of therapeutic proteins, localized within the ciliary muscle cells.
Eyevensys’ lead product EYS606, consists of Eyevensys’ proprietary electro-transfection injection system (ETIS) in combination with plasmid encoding for production of anti-TNFα, for treatment of non-infectious uveitis (NIU). EYS606 is currently in phase I/II clinical trial.
Eyevensys’ vision is to develop a pipeline of therapeutic proteins to address treatment of ophthalmic diseases such as RP, early stage Geographic Atrophy, macular ischemia and other ocular diseases.
Opthea (ASX:OPT) is developing OPT-302, a VEGF-C/D inhibitor for neovascular AMD and DME. VEGF-C/D promote vessel growth and leakage and may contribute to sub-responsiveness to VEGF-A inhibitors. Opthea has reported outcomes from a Phase 1/2a trial in nAMD (n=51) that evaluated safety and clinical activity of OPT-302 as a monotherapy and in combination with ranibizumab in treatment-naïve and prior-treated patients. OPT-302 was well tolerated and data suggest biological activity with improvements in visual acuity and retinal swelling, suggesting additional clinical benefit with dual targeting of VEGF-A and VEGF-C/D. Opthea is currently recruiting patients in two randomised, controlled studies, including a Phase 2b trial of OPT-302 in combination with ranibizumab for nAMD and a Phase 1b/2a trial of OPT-302 in combination with aflibercept for persistent DME.
Trial Runners is a global, niche ophthalmology CRO shaping the future of clinical trials to help others see the world. Founded in 2006, Trial Runners has worked as a partner on over 70 trials and helped over 10,000 patients on the mission to help improve the quality of life of those suffering from ophthalmology-related conditions around the globe. With offices in North Dakota, Texas, Switzerland, and Australia, Trial Runners is ready and able to work on any ophthalmology trial, anywhere in the world.
Utilizing customized strategies, Trial Runners is able to help the pharmaceutical community by providing unique value, innovation, and expertise. Our differentiator is our exceptional team of experts, ready to help our biotechnology and pharmaceutical partners bring their life-improving drugs, devices, and therapies to market.
Bryn Mawr Communications
Bryn Mawr Communications’ (BMC) eye care publications are uniquely positioned in ophthalmology to serve both physicians’ and industry’s needs.
Cataract & Refractive Surgery Today, Cataract & Refractive Surgery Today Europe, Glaucoma Today, Retina Today, MillennialEYE, and CollaborativeEYE showcase in-depth coverage of surgical approaches, device development, pharmacologic innovations, industry trends, and practice management.
By partnering with key opinion leaders, BMC’s eye care publications balance institutional wisdom with fresh perspectives through print magazines, an expansive video library, and timely news feeds. BMC’s in-house production team brings information directly to physicians through live meetings, simulcasted symposia, live surgeries, and more.
Media MICE Pte Ltd was founded in 2009 as a medical publishing and innovative content marketing company based in Singapore, serving both Asia-Pacific and international markets. Media MICE specializes in ophthalmology writing, editing, ophthalmic video creation, databases, publications, content marketing, high-tech communication including virtual reality (VR) and augmented reality (AR), event services, and ophthalmic media creation. The company’s relationships with ophthalmic societies, industry, and ophthalmologists make it the go-to firm for connecting and communicating with these important groups in Asia-Pacific and beyond. Contact director Matt Young at firstname.lastname@example.org for more information. PIE Magazine and CAKE Magazine are all operated by Media MICE Pte Ltd.
Ophthalmology Times is a physician-driven media brand that presents cutting-edge advancements and analysis from around the world in surgery, drug therapy, technology, and clinical diagnosis to elevate the delivery of progressive eye health from physician to patient. Ophthalmology Times’ vision is to be the leading content resource for ophthalmologists. Through its multifaceted content channels, Ophthalmology Times will assist physicians with the tools and knowledge necessary to provide advanced quality patient care in the global world of medicine.
Three key characteristics set The Ophthalmologist apart:
First, we tell stories. We’re able to tell some of the greatest stories in ophthalmology – straight from the people leading the work, in order to educate, inform, influence and entertain.
Second, we provide genuine insight. The team gets it. The Editorial team all have an academic biomedical research background, have written the papers and stood at the podium. We speak “doctor”, we “do” research.
Third, we engage with everyone. Insight comes from observation and conversation. We travel the world to meet and hear what ophthalmologists, entrepreneurs, key industry figures and policymakers have to say – and that’s directly reflected in the content.
Review of Ophthalmology
Review of Ophthalmology is a monthly publication featuring clinically relevant information on surgical technique, new technologies and disease diagnosis and management. Review presents timely articles on ophthalmic subspecialties, such as glaucoma, retina, refractive/cataract surgery, cornea and external disease, pediatric ophthalmology and ocuplastics, as well as current reports on news, regulatory issues, practice management, contact lenses and optical.
touchOPHTHALMOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content.
The US Ophthalmic Review is a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting.
The mission of Ethis, Inc., is to facilitate global innovation in eyecare by providing strategic analysis, exceptional content across a wide range of media, and an extensive network of key ophthalmic and optometric opinion leaders to our industry and academic partners around the world.
Market Scope is the leading source for market data, independent perspective, and objective analysis in today’s ophthalmic marketplace.
Market Scope surveys ophthalmologists regarding procedure volumes, surgical techniques, and product use. This data, along with an extensive database, wide-ranging knowledge of ophthalmic products and technology, and comprehensive network of industry contacts, is used to create more than 20 specialized, yearly reports on the ophthalmic industry.
These reports are used to measure performance, make investment decisions, and allocate resources and serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return on investment decisions in the industry. Market Scope has been committed to ophthalmology for more than 20 years and continues to be the most highly valued source for accurate and timely information about ophthalmic markets.
Women in Ophthalmology (WIO) is the premiere organization for women ophthalmologists aimed at promoting the personal and professional development of women. WIO serves to educate and provide networking opportunities for women ophthalmologists to sharpen their skills and move forward to change the demographics of leadership in ophthalmology. WIO has become an international organization with formal and informal chapters in multiple states and countries. WIO sponsors panels and functions at meetings throughout the world and the Summer Symposium this past summer had nearly 400 attendees from 6 different countries.
Advancing Diversity in Leadership. OWL is a 900+ member professional organization focused on leadership development. Our mission is to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care. We hold local "OWL Connect" events, online learning sessions and Signature Events at ASCRS and AAO.